维卡格雷|Vicagrel |cas:1314081-53-2|西域试剂

维卡格雷,Vicagrel ,98.86%

产品编号：Bellancom-118284| CAS NO：1314081-53-2| 分子式：C₁₈H₁₈ClNO₄S| 分子量：379.86

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-118284	￥3500.00	杭州北京（现货）
Bellancom-118284	￥5500.00	杭州北京（现货）
Bellancom-118284	￥9900.00	杭州北京（现货）
Bellancom-118284	￥16500.00	杭州北京（现货）
Bellancom-118284	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

产品介绍

Vicagrel 是一种有效且安全的抗血小板剂，具有口服活性，通过不可逆地抑制 P2Y12 受体起作用。Viagrel 可用于冠状动脉疾病、外周血管疾病和脑血管疾病中血栓的研究。

生物活性

Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

体外研究

Vicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Vicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats.
Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose.
Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (200−250 g)
Dosage:	3 mg/kg
Administration:	oral
Result:	Inhibitied platelet aggregation by ADP-induced in rats.

Animal Model:	SD male rats
Dosage:	1.14 mg/mL
Administration:	oral, 0-24 h
Result:	Could be readily converted into clopidogrel thiolactone and had high bioavailability.

Animal Model:	Mice
Dosage:	5 g/kg
Administration:	oral, single, for 14 days
Result:	Had very low acute toxicity.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (200−250 g)
Dosage:	3 mg/kg
Administration:	oral
Result:	Inhibitied platelet aggregation by ADP-induced in rats.

Animal Model:	SD male rats
Dosage:	1.14 mg/mL
Administration:	oral, 0-24 h
Result:	Could be readily converted into clopidogrel thiolactone and had high bioavailability.

Animal Model:	Mice
Dosage:	5 g/kg
Administration:	oral, single, for 14 days
Result:	Had very low acute toxicity.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (658.14 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6325 mL	13.1627 mL	26.3255 mL
5 mM	0.5265 mL	2.6325 mL	5.2651 mL
10 mM	0.2633 mL	1.3163 mL	2.6325 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.48 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.48 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. French, et al. Method for preparing vicagrel. Patent. WO2014040498A1.

. Jiaqi Shan, et al. Overcoming clopidogrel resistance: discovery of vicagrel as a highly potent and orally bioavailable antiplatelet agent. J Med Chem [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

维卡格雷,Vicagrel ,98.86%

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询